Get the Stockscreener App
1.68
1.82%
0.03
Curis Inc stock is traded at $1.68, with a volume of 29,034.
It is up +1.82% in the last 24 hours and down -8.70% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.65
Open:
$1.68
24h Volume:
29,034
Relative Volume:
0.28
Market Cap:
$21.00M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.2039
EPS:
-8.24
Net Cash Flow:
$-42.73M
1W Performance:
+5.00%
1M Performance:
-8.70%
6M Performance:
-46.15%
1Y Performance:
-73.87%
1-Day Range:
$1.64
$1.74
1-Week Range:
$1.471
$1.78
52-Week Range:
$1.02
$6.46
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.68 | 21.62M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.34 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.98 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.45 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.37 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis Inc. Stock Approaches Key Moving AverageVolume Spike & AI Optimized Trade Strategies - thegnnews.com
Institutional Tools Highlight Unusual Flow in Curis Inc.July 2025 Macro Moves & AI Powered Trade Plan Recommendations - 선데이타임즈
Traders Consider Averaging Down in Curis Inc.2025 Volume Leaders & Advanced Swing Trade Entry Plans - metal.it
Bollinger Bands Show Potential Breakout in Curis Inc.July 2025 Outlook & Consistent Growth Equity Picks - 선데이타임즈
How Curis Inc. stock performs during market volatilityJuly 2025 Pullbacks & Weekly Setup with ROI Potential - 선데이타임즈
Can Curis Inc. continue delivering strong returnsJuly 2025 Breakouts & Technical Confirmation Trade Alerts - mustnews.co.kr
Market reaction to Curis Inc.’s recent newsAsset Safety Selection Using Quantitative Analysis - Newser
Exit strategy if you’re trapped in Curis Inc.Next Day Momentum Stock Forecasting Report - Newser
What makes Curis Inc. stock price move sharplyGiant Leap Stock Alerts - thegnnews.com
Curis Inc. Receives Buy Rating Due to Promising Clinical Developments and Strong Financial Position. - AInvest
Curis Files Prospectus Supplement for Stock Offering - MSN
Curis Inc. Receives Buy Rating Amid Promising Clinical Developments and Strong Financial Position - TipRanks
Curis targets enrolling 30–40 additional patients for NDA and EMA submissions as emavusertib studies advance - MSN
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st
Curis, Inc. Analysts Trim Price Target After Q2 Report - AInvest
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Curis, Inc. Reports Q2 2025 Financial and Clinical Progress - The Globe and Mail
Curis 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Curis, Inc. shares rise 1.74% intraday as Swiss president meets business leaders in Washington ahead of tariff talks. - AInvest
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Curis, Inc. (NASDAQ:CRIS) Q2 2025 Earnings Call Transcript - Insider Monkey
Curis Provides Second Quarter 2025 Business Update - BioSpace
Curis: Q2 Earnings Snapshot - New Haven Register
Curis Inc. Earnings Call: Progress Amid Challenges - TipRanks
Curis Inc. Q2 Earnings Call Highlights: Progress Amid Challenges - AInvest
Curis (CRIS) Q2 Loss Narrows 66% - The Motley Fool
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy Rating - TipRanks
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises - Investing.com
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises By Investing.com - Investing.com South Africa
Curis Inc: A High-Conviction Biotech Play with Accelerating Catalysts in Hematology - AInvest
Curis, Inc. Q2 2025: Unraveling Contradictions in Enrollment Strategy, FDA Dynamics, and PCNSL Data Expectations - AInvest
Transcript : Curis, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis Inc (CRIS) Q2 2025 Earnings: EPS of -$0.68 Beats Estimate, Revenue Hits $2.7 Million - GuruFocus
Biotech firm Curis Q2 revenue rises to $2.7 mln - MarketScreener
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
How strong is Curis Inc. company’s balance sheetTrack top-performing stocks effortlessly - Jammu Links News
What are the technical indicators suggesting about Curis Inc.Exceptional gains - Jammu Links News
Curis Inc Q2 2025 Earnings Report Preview: Revenue Expected to Reach $2.64 Million, Earnings at -$1.36 per Share - AInvest
What catalysts could drive Curis Inc. stock higher in 2025Achieve breakthrough investment performance - Jammu Links News
How does Curis Inc. compare to its industry peersGet real-time updates on market trends - Jammu Links News
What drives Curis Inc. stock priceUnmatched market gains - Jammu Links News
What are Curis Inc. company’s key revenue driversInvest smarter with daily trading signals - Jammu Links News
What are analysts’ price targets for Curis Inc. in the next 12 monthsTurn volatility into profit opportunities - Jammu Links News
What is Curis Inc. company’s growth strategyBreakthrough financial growth - Jammu Links News
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):